Immunoregulatory T cell epitope peptides: The new frontier in allergy therapy

Clinical and Experimental Allergy

Volumn 45, Issue 6, 2015, Pages 1015-1026

  Prickett, S R ^a   Rolland, J M ^a   O'Hehir, R E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BEE VENOM; EPITOPE; SYNTHETIC PEPTIDE; HLA ANTIGEN CLASS 2; IMMUNOLOGIC FACTOR; PEPTIDE;

ALLELE; ALLERGIC DISEASE; ALLERGY; AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DERMATOPHAGOIDES; DOWN REGULATION; EPITOPE MAPPING; GRASS POLLEN; HLA SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MURINE MODEL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; TH2 CELL; ANIMAL; ANTIGEN PRESENTATION; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; PRECLINICAL STUDY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ALLERGENS; ANIMALS; ANTIGEN PRESENTATION; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYPERSENSITIVITY; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PEPTIDES; T-LYMPHOCYTE SUBSETS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84929309946     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12554     Document Type: Review

References (120)

1. Burks AW, Calderon MA, Casale T et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013; 131:1288-96 e3.
2. Canonica GW, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64(Suppl 91):1-59.
3. Pfaar O, Demoly P, Gerth van Wijk R et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014; 69:854-67.
4. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 177:1555-626.
5. Bauer CS, Rank MA. Comparative efficacy and safety of subcutaneous versus sublingual immunotherapy. J Allergy Clin Immunol 2014; 134:765.e2.
6. Chelladurai Y, Suarez-Cuervo C, Erekosima N et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. J Allergy Clin Immunol Pract 2013; 1:361-9.
7. Kiel MA, Roder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Molken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013; 132:353-60 e2.
8. Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981; 68:449-59.
9. Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82:439-46.
10. Negro JM, Wheeler AW, Hernandez J et al. Comparison of the efficacy and safety of two preseasonal regimens of glutaraldehyde modified, tyrosine-adsorbed parietaria pollen extract over a period of three years in monosensitive patients. Allergol Immunopathol (Madr) 1999; 27:153-64.
11. Pellaton C, Perrin Y, Boudousquie C et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy 2013; 3:17.
12. Spertini F, Perrin Y, Audran R et al. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J Allergy Clin Immunol 2014; 134:239-40e13.
13. Valenta R, Niespodziana K, Focke-Tejkl M et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011; 127:860-4.
14. Kay AB. Allergy and allergic diseases. Second of two parts. N Engl J Med 2001; 344:109-13.
15. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344:30-7.
16. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014; 133:621-31.
17. Wambre E, DeLong JH, James EA, LaFond RE, Robinson D, Kwok WW. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol 2012; 129:544-51 e1-7.
18. Wambre E, DeLong JH, James EA et al. Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner. J Allergy Clin Immunol 2014; 133:872-9 e7.
19. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-13.
20. Han D, Wang C, Lou W, Gu Y, Wang Y, Zhang L. Allergen-specific IL-10-secreting type I T regulatory cells, but not CD4(+)CD25(+)Foxp3(+) T cells, are decreased in peripheral blood of patients with persistent allergic rhinitis. Clin Immunol 2010; 136:292-301.
21. Ajduk J, Marinic I, Aberle N, Rabatic S, Gagro A. Effect of house dust mite immunotherapy on transforming growth factor beta1-producing T cells in asthmatic children. Ann Allergy Asthma Immunol 2008; 100:314-22.
22. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.
23. van de Veen W, Stanic B, Yaman G et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013; 131:1204-12.
24. Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol 2010; 11:674-80.
25. Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res 2010; 20:4-12.
26. Verhoef A, Higgins JA, Thorpe CJ et al. Clonal analysis of the atopic immune response to the group 2 allergen of Dermatophagoides spp.: identification of HLA-DR and -DQ restricted T cell epitopes. Int Immunol 1993; 5:1589-97.
27. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358:155-7.
28. Wedderburn LR, O'Hehir RE, Hewitt CR, Lamb JR, Owen MJ. In vivo clonal dominance and limited T-cell receptor usage in human CD4+ T-cell recognition of house dust mite allergens. Proc Natl Acad Sci USA 1993; 90:8214-8.
29. Aslam A, Chan H, Warrell DA, Misbah S, Ogg GS. Tracking antigen-specific T-cells during clinical tolerance induction in humans. PLoS One 2010; 5:e11028.
30. O'Hehir RE, Lake RA, Schall TJ, Yssel H, Panagiotopoulou E, Lamb JR. Regulation of cytokine and chemokine transcription in a human TH2 type T-cell clone during the induction phase of anergy. Clin Exp Allergy 1996; 26:20-7.
31. Hoyne GF, Askonas BA, Hetzel C, Thomas WR, Lamb JR. Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo. Int Immunol 1996; 8:335-42.
32. O'Hehir RE, Young DB, Kay AB, Lamb JR. Cloned human T lymphocytes reactive with Dermatophagoides farinae (house dust mite): a comparison of T- and B-cell antigen recognition. Immunology 1987; 62:635-40.
33. O'Hehir RE, Askonas BA, Lamb JR. Cell culture: lymphocyte clones. In: Albert WHW, Staines NA, eds. Methods of immunological analysis 3. Springer-Verlag: Heidelberg, 1993:120-38.
34. Mannering SI, Dromey JA, Morris JS, Thearle DJ, Jensen KP, Harrison LC. An efficient method for cloning human autoantigen-specific T cells. J Immunol Methods 2005; 298:83-92.
35. Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol 2011; 127:608-15 e1-5.
36. Oseroff C, Sidney J, Kotturi MF et al. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol 2010; 185:943-55.
37. Kwok WW, Roti M, Delong JH et al. Direct ex vivo analysis of allergen-specific CD4+ T cells. J Allergy Clin Immunol 2010; 125:1407-9 e1.
38. Van Hemelen D, Mahler V, Fischer G et al. HLA class II peptide tetramers vs allergen-induced proliferation for identification of allergen-specific CD4 T cells. Allergy 2015; 70:49-58.
39. Tye-Din JA, Stewart JA, Dromey JA et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2010; 2:41ra51.
40. Bateman EA, Ardern-Jones MR, Ogg GS. Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopes.[see comment]. Clin Exp Allergy 2008; 38:1760-8.
41. Schulten V, Oseroff C, Alam R et al. The identification of potentially pathogenic and therapeutic epitopes from common human allergens. Ann Allergy Asthma Immunol 2013; 110:7-10.
42. Lundegaard C, Lund O, Nielsen M. Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy? Expert Rev Vaccines 2012; 11:43-54.
43. Burton MD, Blaher B, Suphioglu C, O'Hehir RE, Carbone FR, Rolland JM. T-cell receptor contact and MHC binding residues of a major rye grass pollen allergen T-cell epitope. J Allergy Clin Immunol 1999; 103:255-61.
44. Knapp B, Fischer G, Van Hemelen D et al. Association of HLA-DR1 with the allergic response to the major mugwort pollen allergen: molecular background. BMC Immunol 2012; 13:43.
45. Knapp B, Omasits U, Bohle B et al. 3-Layer-based analysis of peptide-MHC interaction: in silico prediction, peptide binding affinity and T cell activation in a relevant allergen-specific model. Mol Immunol 2009; 46:1839-44.
46. Maillere B, Mourier G, Herve M, Menez A. Fine chemical modifications at N- and C-termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC-complexed peptides. Mol Immunol 1995; 32:1377-85.
47. Mutschlechner S, Egger M, Briza P et al. Naturally processed T cell-activating peptides of the major birch pollen allergen. J Allergy Clin Immunol 2010; 125:711-8, 8 e1-8 e2.
48. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353:622-7.
49. Salimi N, Fleri W, Peters B, Sette A. The immune epitope database: a historical retrospective of the first decade. Immunology 2012; 137:117-23.
50. Vita R, Zarebski L, Greenbaum JA et al. The immune epitope database 2.0. Nucleic Acids Res 2010; 38:D854-62.
51. Vaughan K, Greenbaum J, Kim Y et al. Towards defining molecular determinants recognized by adaptive immunity in allergic disease: an inventory of the available data. J Allergy (Cairo) 2010; 2010:628026.
52. Gammon G, Sercarz E. How some T cells escape tolerance induction. Nature 1989; 342:183-5.
53. Etto T, de Boer C, Prickett S et al. Unique and cross-reactive T cell epitope peptides of the major Bahia grass pollen allergen, Pas n 1. Int Arch Allergy Immunol 2012; 159:355-66.
54. Glaspole IN, de Leon MP, Prickett SR, O'Hehir RE, Rolland JM. Clinical allergy to hazelnut and peanut: identification of T cell cross-reactive allergens. Int Arch Allergy Immunol 2011; 155:345-54.
55. Jahn-Schmid B, Radakovics A, Luttkopf D et al. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005; 116:213-9.
56. Sone T, Dairiki K, Morikubo K et al. Identification of human T cell epitopes in Japanese cypress pollen allergen, Cha o 1, elucidates the intrinsic mechanism of cross-allergenicity between Cha o 1 and Cry j 1, the major allergen of Japanese cedar pollen, at the T cell level. Clin Exp Allergy 2005; 35:664-71.
57. Schenk S, Breiteneder H, Susani M et al. T-cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): evidence for crossreacting and non-crossreacting T-cell epitopes within grass group I allergens. J Allergy Clin Immunol 1995; 96:986-96.
58. Drew AC, Eusebius NP, Kenins L et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 2004; 173:5872-9.
59. Prickett SR, Voskamp AL, Phan T et al. Ara h 1 CD4+ T-cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clin Exp Allergy 2013; 43:684-97.
60. Worm M, Lee HH, Kleine-Tebbe J et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011; 127:89-97, e1-14.
61. Santos AF, Douiri A, Becares N et al. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. J Allergy Clin Immunol 2014; 134:645-52.
62. O'Hehir RE, Eckels DD, Frew AJ, Kay AB, Lamb JR. MHC class II restriction specificity of cloned human T lymphocytes reactive with Dermatophagoides farinae (house dust mite). Immunology 1988; 64:627-31.
63. O'Hehir RE, Mach B, Berte C et al. Direct evidence for a functional role of HLA-DRB1 and -DRB3 gene products in the recognition of Dermatophagoides spp. (house dust mite) by helper T lymphocytes. Int Immunol 1990; 2:885-92.
64. Higgins JA, Lamb JR, Marsh SG et al. Peptide-induced nonresponsiveness of HLA-DP restricted human T cells reactive with Dermatophagoides spp. (house dust mite). J Allergy Clin Immunol 1992; 90:749-56.
65. McKinney DM, Southwood S, Hinz D et al. A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics 2013; 65:357-70.
66. ® Class II Rapid Epitope Discovery System (Last accessed 24 April 2015). Available from: https://www.proimmune.com/ecommerce/page.php?page=reveal_class2.
67. Nepom GT. MHC class II tetramers. J Immunol 2012; 188:2477-82.
68. Jahn-Schmid B, Pickl WF, Bohle B. Interaction of allergens, major histocompatibility complex molecules, and T cell receptors: a 'menage a trois' that opens new avenues for therapeutic intervention in type I allergy. Int Arch Allergy Immunol 2011; 156:27-42.
69. Crack LR, Chan HW, McPherson T, Ogg GS. Identification of an immunodominant region of the major house dust mite allergen Der p 2 presented by common human leucocyte antigen alleles. Clin Exp Dermatol 2012; 37:266-76.
70. Friedl-Hajek R, Spangfort MD, Schou C, Breiteneder H, Yssel HJoost van Neerven RJ. Identification of a highly promiscuous and an HLA allele-specific T-cell epitope in the birch major allergen Bet v 1: HLA restriction, epitope mapping and TCR sequence comparisons. Clin Exp Allergy 1999; 29:478-87.
71. DeLong JH, Simpson KH, Wambre E, James EA, Robinson D, Kwok WW. Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol 2011; 127:1211-8 e3.
72. van Neerven RJ, van de Pol MM, van Milligen FJ, Jansen HM, Aalberse RC, Kapsenberg ML. Characterization of cat dander-specific T lymphocytes from atopic patients. J Immunol 1994; 152:4203-10.
73. Yssel H, Johnson KE, Schneider PV et al. T cell activation-inducing epitopes of the house dust mite allergen Der p I. Proliferation and lymphokine production patterns by Der p I-specific CD4+ T cell clones. J Immunol 1992; 148:738-45.
74. Castelli FA, Buhot C, Sanson A et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 2002; 169:6928-34.
75. O'Hehir RE, Yssel H, Verma S, de Vries JE, Spits H, Lamb JR. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol 1991; 3:819-26.
76. O'Hehir RE, Aguilar BA, Schmidt TJ, Gollnick SO, Lamb JR. Functional inactivation of Dermatophagoides spp. (house dust mite) reactive human T-cell clones. Clin Exp Allergy 1991; 21:209-15.
77. Fasler S, Aversa G, Terr A, Thestrup-Pedersen K, de Vries JE, Yssel H. Peptide-induced anergy in allergen-specific human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. Reversal by IL-2, not by IL-4 or IL-13. J Immunol 1995; 155:4199-206.
78. Lake RA, O'Hehir RE, Verhoef A, Lamb JR. CD28 mRNA rapidly decays when activated T cells are functionally anergized with specific peptide. Int Immunol 1993; 5:461-6.
79. Faith A, Akdis CA, Akdis M, Simon HU, Blaser K. Defective TCR stimulation in anergized type 2 T helper cells correlates with abrogated p56(lck) and ZAP-70 tyrosine kinase activities. J Immunol 1997; 159:53-60.
80. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993; 178:1783-8.
81. O'Hehir RE, Hoyne GF, Thomas WR, Lamb JR. House dust mite allergy: from T-cell epitopes to immunotherapy. Eur J Clin Invest 1993; 23:763-72.
82. Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993; 90:7608-12.
83. Bauer L, Bohle B, Jahn-Schmid B et al. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol 1997; 107:536-41.
84. Yoshitomi T, Nakagami Y, Hirahara K, Taniguchi Y, Sakaguchi M, Yamashita M. Intraoral administration of a T-cell epitope peptide induces immunological tolerance in Cry j 2-sensitized mice. J Pept Sci 2007; 13:499-503.
85. Hirahara K, Saito S, Serizawa N et al. Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific TH1 and TH2 cell responses in Cry j 2-primed mice. J Allergy Clin Immunol 1998; 102:961-7.
86. Marazuela EG, Rodriguez R, Fernandez-Garcia H, Garcia MS, Villalba M, Batanero E. Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen. Mol Immunol 2008; 45:438-45.
87. King TP, Lu G, Agosto H. Antibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell epitope peptides. J Allergy Clin Immunol 1998; 101:397-403.
88. Astori M, von Garnier C, Kettner A, Dufour N, Corradin G, Spertini F. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J Immunol 2000; 165:3497-505.
89. Campbell JD, Buckland KF, McMillan SJ et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009; 206:1535-47.
90. Rupa P, Mine Y. Oral immunotherapy with immunodominant T-cell epitope peptides alleviates allergic reactions in a Balb/c mouse model of egg allergy. Allergy 2012; 67:74-82.
91. Till SJ, Raynsford EJ, Reynolds CJ et al. Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax 2014; 69:335-45.
92. Hoyne GF, Jarnicki AG, Thomas WR, Lamb JR. Characterization of the specificity and duration of T cell tolerance to intranasally administered peptides in mice: a role for intramolecular epitope suppression. Int Immunol 1997; 9:1165-73.
93. Mackenzie KJ, Fitch PM, Leech MD et al. Combination peptide immunotherapy based on T-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation. Immunology 2013; 138:258-68.
94. Muller U, Akdis CA, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:747-54.
95. Fellrath JM, Kettner A, Dufour N et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111:854-61.
96. Wallner BP, Gefter ML. Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy 1994; 49:302-8.
97. Norman PS, Ohman JL Jr, Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623-8.
98. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999; 189:1885-94.
99. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999; 93:222-31.
100. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8:1937-45.
101. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47-53.
102. Larche M. Peptide immunotherapy for allergic diseases. Allergy 2007; 62:325-31.
103. Larche M. T cell epitope-based allergy vaccines. Curr Top Microbiol Immunol 2011; 352:107-19.
104. Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs 2013; 22:1347-57.
105. Smith TR, Alexander C, Kay AB, Larche M, Robinson DS. Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study. Allergy 2004; 59:1097-101.
106. Couroux P, Patel D, Armstrong K, Larche M, Hafner RP. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy 2015; 45:974-81.
107. Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M. The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy 2013; 3:42.
108. Durham SR. Sublingual immunotherapy: what have we learnt from the 'big trials'? Curr Opin Allergy Clin Immunol 2008; 8:577-84.
109. Larche M, Hickey P, Hebert J, Hafner R. Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD). J Allergy Clin Immunol 2013; 131:AB37.
110. Hafner RP, Couroux P, Armstrong K, Salapatek AM, Patel D, Larche M. Four doses of Der p derived synthetic peptide immuno-regulatory epitopes over 3 months results in a persistent treatment effect at 1 year on symptoms of House Dust Mite allergy. Allergy 2014; 69:31-2.
111. Ellis AK, Frankish CW, Armstrong K et al. A short course of synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a reduction in grass allergy symptoms. Allergy 2014; 69:32.
112. Hafner R, Salapatek A, Patel D, Larche M, Laidler P. Validation of peptide immunotherapy as a new approach in the treatment of allergic rhinoconjunctivitis: the clinical benefits of treatment with Amb a 1-derived T cell epitopes. J Allergy Clin Immunol 2012; 129:AB368.
113. Larche M. Mechanisms of peptide immunotherapy in allergic airways disease. Ann Am Thorac Soc 2014; 11(Suppl 5):S292-6.
114. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11:S69-76.
115. O'Hehir RE, Sandrini A, Anderson GP, Rolland JM. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr Med Chem 2007; 14:2235-44.
116. Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36:465-74.
117. Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005; 2:e78.
118. Alexander C, Ying S, Kay AB, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005; 35:52-8.
119. Rolland JM, Gardner LM, O'Hehir RE. Functional regulatory T cells and allergen immunotherapy. Curr Opin Allergy Clin Immunol 2010; 10:559-66.
120. Plaut M, Rotrosen D. Tolerance induced by allergen immunotherapy. Clin Allergy Immunol 2004; 18:681-702.